SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00...
SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic,...
SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational...
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth
SAN DIEGO , Oct. 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT ® ...
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Neurocrine, with a price target of $180.00. The company’s shares closed yesterday at $137.35.Elevate Your Investing...
RBC Capital analyst Brian Abrahams maintained a Buy rating on Neurocrine today and set a price target of $156.00. The company’s shares opened today at $137.87.Elevate Your Investing Strategy: Take advantage...
Conference Call and Webcast Scheduled for Tuesday, October 28